Mental Health

The US Food and Drug Administration has approved expanding the label of a psoriasis drug to include adults with moderate-to-severe plaque psoriasis.

The US Food and Drug Administration has approved a subcutaneous injection for the treatment of a rare and serious genetic disease involving the inability to break down phenylananine.

The US Food and Drug Administration has approved a subcutaneous injection for the treatment of a rare and serious genetic disease involving the inability to break down phenylananine.

The US Food and Drug Administration has approved a subcutaneous injection for the treatment of a rare and serious genetic disease involving the inability to break down phenylananine.

See what hematology news your colleagues have been reading.

See what hematology news your colleagues have been reading.

See what hematology news your colleagues have been reading.

The FDA has approved a label update for a biologic used for the treatment of adult patients with moderate-to-severe plaque psoriasis

The FDA has approved a label update for a biologic used for the treatment of adult patients with moderate-to-severe plaque psoriasis

The US Food and Drug Administration has approved a fifth indication for a human monoclonal antibody commonly used for the treatment of osteoporosis.